Precision med startup PreciThera nets $29 mln in Series A round
Precision medicine company PreciThera Inc has raised $29 million in Series A financing. The round, which follows PreciThera’s seed funding in May, was backed by Sanderling Ventures, Arix Bioscience, Fonds de solidarité FTQ, CTI Life Sciences and Emerillon Capital. Montréal-based PreciThera is focused on designing biological therapeutics for the treatment of orphan bone diseases.
27 July 2017•5 mins read
